Gilead Sciences' Q3 2024 results exceeded expectations, driven by a strong performance of the HIV portfolio. Read why I ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Deadly fungi including Candida auris have been spreading. Gilead and Merck are two pharma stocks worth owning amidst fungal ...

Merck, Gilead Sciences, and Novartis all offer generous dividend yields. These companies all have underrated growth prospects in the long run. At low valuations, they can be no-brainer buys for ...

On average, equities research analysts anticipate that Gilead Sciences will post 3.78 EPS for the current fiscal year. The business also recently announced a quarterly dividend, which was paid on ...

For income investors, GILD also offers a quarterly dividend of $0.77 per share with a yield of 3.49%, and has been raising its dividends for nine years in a row. Gilead Sciences reported solid ...

InvestingPro Tips highlight Gilead's attractive dividend profile, noting that the company "has raised its dividend for 9 consecutive years." This consistent dividend growth, coupled with a current ...

Pharmaceutical titan Merck pays investors a dividend that yields 2.8% -- more ... Investors can secure an even higher-yielding stock with Gilead Sciences. It currently pays 3.6%, and this is ...